Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2

Molecular Carcinogenesis

Volumn 23, Issue 1, 1998, Pages 36-44

  Muller Decker K ^a   Kopp Schneider, A ^b   Marks, F ^a   Seibert, K ^c   Furstenberger G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Central Unit Biostatistics

^c PFIZER INC   (United States)

Author keywords

Chemoprevention; Cyclooxygenase; Immunohistochemistry; Keratinocyte; Langerhans cell; Multistage skin carcinogenesis; Nonsteroidal anti inflammatory drug; Prostaglandin H synthase; SC 58125

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; DIMETHYLBENZ[A]ANTHRACENE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME LOCALIZATION; FEMALE; GENE MUTATION; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LANGERHANS CELL; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT; SKIN CARCINOGENESIS; SKIN TUMOR;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EPIDERMIS; FEMALE; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

ANIMALIA; MURINAE;

EID: 0031658940     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F     Document Type: Article

References (39)

1. Kinzler KW, Vogelstein B. Lessons learned from hereditary colorectal cancer. Cell 87:159-170, 1996.
2. Parsonnet J. Molecular mechanisms for inflammation-promoted pathogenesis of cancer - The sixteenth international symposium of the Sapporo Cancer Seminar. Cancer Res 57:3620-3624, 1997.
3. Marks F, Fürstenberger G. Proliferative responses of the skin to external stimuli. Environ Health Perspect 101:95-102, 1993.
4. Schwarz M. Tumor Promotion in Liver. In: Arcos JC (ed) Chemical Induction of Cancer, Birkhäuser, Boston, 1995, pp. 161-179.
5. Fürstenberger G, Kopp-Schneider A. Malignant progression of papillomas induced by the initiation-promotion protocol in NMRI mouse skin. Carcinogenesis 16:61-69, 1995.
6. Brown K, Bums PA, Balmain A. Transgenic approaches to understanding the mechanisms of chemical carcinogenesis in mouse skin. Toxicol Lett 82-83:123-130, 1995.
7. Marks F, Fürstenberger G, Heinzelmann T, Müller-Decker K. Mechanisms in tumor promotion: Guidance for risk assessment and cancer chemoprevention. Toxicol Lett 82-83:907-917, 1995.
8. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 13:303-308, 1994.
9. Müller-Decker K, Scholz K, Marks F, Fürstenberger G. Differential expression of prostaglandin H synthase isoenzymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog 12:31-41, 1995.
10. Fürstenberger G, Gross M, Marks F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandin E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 10:91-96, 1989.
11. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160, 1996.
12. Scholz K, Fürstenberger G, Müller-Decker K, Marks F. Differential expression of prostaglandin-H synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro. Biochem J 309:263-269, 1995.
13. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017, 1994.
14. Gschwendt M, Kittstein W, Fürstenberger G, Marks F. The mouse ear edema: A quantitatively evaluable assay for tumor promoting compounds and for inhibitors of tumor promotion. Cancer Lett 25:177-185, 1984.
15. Harlow E, Lane D. Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988.
16. Hollander M, Wolfe DA. Nonparametric Statistical Methods. J. Wiley & Sons, New York, 1973.
17. Kalbfleisch KD, Prentice RL. The Statistical Analysis of Failure Time Data. J. Wiley & Sons, New York, 1980.
18. Mertz PM, DeWitt DL, Stetlet-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. J Biol Chem 296:21322-21329, 1994.
19. 2 generation in mouse osteoblastic cells. J Biol Chem 272:19891-19897, 1997.
20. Fröhlich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 18:30-34, 1997.
21. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589, 1992.
22. Müller-Decker K, Scholz K, Neufang G, Marks F, Fürstenberger G. Localization of prostaglandin-H synthase-1 and -2 in mouse skin: Implications for cutaneous function. Exp Cell Res, in press.
23. Marks F, Fürstenberger G, Kownatzki E. Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A 23187 and by tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 41:696-702, 1981.
24. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501, 1995.
25. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11:234-247, 1997.
26. Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87:783-786, 1996.
27. DuBois RN, Radhika A, Reddy BS, Eutingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110:1259-1262, 1996.
28. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996.
29. Eberhard CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994.
30. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559, 1995.
31. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789, 1995.
32. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 93:4816-4820, 1996.
33. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996.
34. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340, 1997.
35. Tiano H, Chulada P, Spalding J, et al. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Carcinogenesis 6:257, 1997.
36. Burns FJ, Vanderlaan M, Sivak A, Albert RE. Regression kinetics of mouse skin papillomas. Cancer Res 36:1422-1427, 1976.
37. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1-20, 1997.
38. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566-4569, 1996.
39. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-412, 1998.